AR091977A1 - El uso de antitrombina en la oxigenacion de membranas extracorporeas - Google Patents

El uso de antitrombina en la oxigenacion de membranas extracorporeas

Info

Publication number
AR091977A1
AR091977A1 ARP130102756A ARP130102756A AR091977A1 AR 091977 A1 AR091977 A1 AR 091977A1 AR P130102756 A ARP130102756 A AR P130102756A AR P130102756 A ARP130102756 A AR P130102756A AR 091977 A1 AR091977 A1 AR 091977A1
Authority
AR
Argentina
Prior art keywords
oxygenation
extracorpore
antitrombin
membranes
antithrombin
Prior art date
Application number
ARP130102756A
Other languages
English (en)
Spanish (es)
Original Assignee
Revo Biolog Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revo Biolog Inc filed Critical Revo Biolog Inc
Publication of AR091977A1 publication Critical patent/AR091977A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ARP130102756A 2012-08-03 2013-08-02 El uso de antitrombina en la oxigenacion de membranas extracorporeas AR091977A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261679345P 2012-08-03 2012-08-03

Publications (1)

Publication Number Publication Date
AR091977A1 true AR091977A1 (es) 2015-03-11

Family

ID=50028554

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102756A AR091977A1 (es) 2012-08-03 2013-08-02 El uso de antitrombina en la oxigenacion de membranas extracorporeas

Country Status (13)

Country Link
US (1) US9511087B2 (https=)
EP (1) EP2879697A4 (https=)
JP (1) JP6389172B2 (https=)
KR (1) KR20150039201A (https=)
CN (1) CN104884080A (https=)
AR (1) AR091977A1 (https=)
AU (1) AU2013296240B2 (https=)
BR (1) BR112015002321A2 (https=)
CA (1) CA2879763C (https=)
IL (1) IL236776A0 (https=)
MX (1) MX2015001508A (https=)
TW (1) TW201425332A (https=)
WO (1) WO2014022748A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140093603A (ko) 2010-12-30 2014-07-28 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 병원체 불활성화제로서의 글리콜
TW201425332A (zh) 2012-08-03 2014-07-01 Revo Biolog Inc 抗凝血酶用於體外膜氧合之用途
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
EP3594231A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
MX384222B (es) 2013-07-05 2025-03-14 Lab Francais Du Fractionnement Matriz de cromatografia de afinidad.
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
EP3388140A1 (en) * 2017-04-10 2018-10-17 Gambro Lundia AB Extracorporeal blood circuit

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517294A (en) 1982-03-03 1985-05-14 Genentech, Inc. Human antithrombin III
US4632981A (en) 1982-07-30 1986-12-30 Genentech, Inc. Human antithrombin III
US6727405B1 (en) 1986-04-09 2004-04-27 Genzyme Corporation Transgenic animals secreting desired proteins into milk
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US5366894A (en) 1986-06-30 1994-11-22 Pharmaceutical Proteins Limited Peptide production
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5439446A (en) 1994-06-30 1995-08-08 Boston Scientific Corporation Stent and therapeutic delivery system
DE4028800A1 (de) 1990-09-11 1992-03-12 Behringwerke Ag Gentechnische sialylierung von glykoproteinen
DE4326665C2 (de) 1993-08-09 1995-07-13 Biotest Pharma Gmbh Verfahren zur Sterilfiltration von Milch
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5843705A (en) * 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US5801063A (en) * 1995-05-09 1998-09-01 Grandics; Peter Device and process for the biospecific removal of heparin
US6268487B1 (en) 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
WO1998037224A1 (en) 1997-02-25 1998-08-27 Genzyme Transgenics Corporation Transgenically produced non-secreted proteins
US20060264357A1 (en) 1997-04-22 2006-11-23 Zikria Bashir A Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals
US8257724B2 (en) 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
DE10159556A1 (de) 2001-12-05 2003-06-12 Aventis Behring Gmbh Intellect Antithrombin III zur Präventation und Therapie vaskuloproliferativer Erkrankungen
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US7191068B2 (en) 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
CN1871252A (zh) 2003-09-05 2006-11-29 Gtc生物治疗学公司 在转基因哺乳动物奶中生产融合蛋白的方法
CA2479968A1 (en) 2004-09-01 2006-03-01 Keith R. Walley Protein c and endothelial protein c receptor polymorphisms as indicators of patient outcome
EP1776108A1 (en) 2004-06-23 2007-04-25 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
AU2006261555A1 (en) 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor lll polymorphisms associated with prediction of subject outcome and response to therapy
WO2007014244A2 (en) 2005-07-25 2007-02-01 Gtc Biotherapeutics, Inc. Method of purifying recombinant human antithrombin to enhance the viral and prion safety profile
KR20080068089A (ko) 2005-10-21 2008-07-22 지티씨바이오쎄라퓨틱스,인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및사용 방법
US20070292407A1 (en) 2005-12-12 2007-12-20 The Board Of Trustees Operating Michigan State University Methods of treatment for meconium aspiration syndrome
US7531632B2 (en) 2006-02-16 2009-05-12 Gtc Biotherapeutics, Inc. Clarification of transgenic milk using depth filtration
US8173860B2 (en) 2006-04-21 2012-05-08 Gtc Biotherapeutics, Inc. Non-human transgenic mammal expressing a human FcRn on its mammary gland cells and expressing a transgenic protein-human Fc-domain fusion
WO2009097584A1 (en) 2008-01-30 2009-08-06 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
US20110082083A1 (en) 2009-04-10 2011-04-07 Gtc Biotherapeutics, Inc. Formulations of liquid stable antithrombin
US8551096B2 (en) 2009-05-13 2013-10-08 Boston Scientific Scimed, Inc. Directional delivery of energy and bioactives
KR20140054026A (ko) 2011-07-07 2014-05-08 알에보 바이올로직스, 인코포레이티드 단백질을 안정화시키는 제제
TW201400499A (zh) 2012-03-12 2014-01-01 Revo Biolog Inc 抗凝血酶用於治療妊娠毒血症之用途
TW201425332A (zh) 2012-08-03 2014-07-01 Revo Biolog Inc 抗凝血酶用於體外膜氧合之用途

Also Published As

Publication number Publication date
KR20150039201A (ko) 2015-04-09
AU2013296240A1 (en) 2015-02-12
US20140194360A1 (en) 2014-07-10
US9511087B2 (en) 2016-12-06
CA2879763C (en) 2020-12-01
AU2013296240B2 (en) 2018-05-17
JP2015524823A (ja) 2015-08-27
BR112015002321A2 (pt) 2019-10-22
EP2879697A1 (en) 2015-06-10
CN104884080A (zh) 2015-09-02
JP6389172B2 (ja) 2018-09-12
IL236776A0 (en) 2015-03-31
MX2015001508A (es) 2015-04-08
CA2879763A1 (en) 2014-02-06
EP2879697A4 (en) 2016-01-20
WO2014022748A1 (en) 2014-02-06
TW201425332A (zh) 2014-07-01

Similar Documents

Publication Publication Date Title
AR091977A1 (es) El uso de antitrombina en la oxigenacion de membranas extracorporeas
MX2021001867A (es) Administracion y monitoreo de oxidio nitrico en fluidos ex vivo.
MX2015009416A (es) Anticuerpos humanos de la proteina f del virus respiratorio sincitial y metodos de uso de estos.
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
BR112016016290A2 (pt) Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina
CR20170279A (es) Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
CO7190239A2 (es) Dialisato a base de polímero
BR112016010103A8 (pt) métodos, kits e dispositivos de suprimento de fármaco osmótico.
MX362597B (es) Sistema y metodo para intercambio de dialisis peritoneal teniendo una unidad energizante reutilizable.
CL2012003038A1 (es) Polietilenglicol conjugado a factor viia; composicion farmacéutica que comprende dicho polietilenglicol conjugado a factor viia; uso de una composicion farmaceutica para tratar enfermedad o trauma de la coagulacion de la sangre en un paciente que la necesita; proceso para preparar el siguiente polietilenglicol conjugado a factor viia.
BR112015012014A2 (pt) proteínas de ligação específicas duais penetrando a barreira hematoencefálica (bbb)
CL2015002747A1 (es) Metodo para la oxigenacion extracorporea de un sujeto; y aparato de incubacion.
PE20150226A1 (es) Agentes terapeuticos para administracion subcutanea optimizados
BR112016026243A2 (pt) membrana, molécula de fibra oca, uso de uma membrana, e, copolímero em bloco
DOP2016000102A (es) (aza)piridopirazolopirimidinonas e indazolopirimidinonas y su uso
CL2013001382A1 (es) Metodo para aumentar la seguridad y la eficacia de las transfusiones de sangre, que comprende administrar a un paciente una composicion farmaceutica que comprende un copolimero de polioxietileno/polioxipropileno, en donde la composicion se mezcla con la sangre antes de la transfusion, o se administra al paciente antes o despues de la transfusion.
GT200900319A (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
ECSP10010553A (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
DK2175877T3 (da) Anvendelse af muterede antitrombiner til behandling eller forebyggelse af koagulationssygdomme
CL2015001943A1 (es) Derivados de bencilamina
NI201000181A (es) Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona.
CL2013000021A1 (es) Forma cristalina delta de la sal de arginina de perindoprilo; procedimiento de preparacion; composiciones farmaceuticas que la contienen; y su uso par el tratamiento de las enfermedades cardiovasculares, tales como hipertension arterial, insuficiencia cardiaca o enfermedad coronaria estable.
UA112488C2 (uk) Три(гетеро)арилпіразоли і їх застосування
MX2017014731A (es) Eliminacion de linfocitos b como marcador diagnostico.

Legal Events

Date Code Title Description
FB Suspension of granting procedure